bullish
Raffles Medical (RFMD SP): Resilient Business Model; Border Reopening to Further Boost Growth
485 Views10 May 2022 20:32
SUMMARY
- Raffles Medical (RFMD SP) reported 27% y/y revenue growth to S$723.8 million and net profit increase of 30% y/y to S$83.7 million in 2021.
- Following full border reopening by Singapore beginning April, medical tourism is set to revive. As a leading hospital operator in Singapore, Raffles is well-positioned to grab the opportunity.
- Regular share buyback and recent stake increase by a major investor further enhance conviction on the company’s growth potential.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Raffles Medical (RFMD SP): 2022 Result Tops Expectation; Medical Tourism Resumption to Drive Growth27 Feb 2023
- Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism02 Aug 2022
- Fraser Hospitality Trust (FRHO): Privatization + Recovery.20 May 2022
- Raffles Medical (RFMD SP) - Pivot in SG Travel Rules, Testing Regime and Its Implications17 Feb 2022
- Raffles Medical – Uplift from Singapore COVID-19 Strategy Pivot and Border Re-Opening11 Jul 2021
x